SS-31

SS-31, also known as Elamipretide, Bendavia, MTP-131, or Forzinity, represents a groundbreaking mitochondrial peptide that has garnered significant attention in cellular research. This mitochondria-targeting compound operates through a unique mechanism involving selective binding to cardiolipin, a specialised lipid found exclusively within the inner mitochondrial membrane. In research models, SS-31 demonstrates remarkable efficacy in stabilising cardiolipin structures, which proves crucial for maintaining optimal mitochondrial architecture and function. This stabilisation process leads to a cascade of beneficial cellular effects, including reduced production of reactive oxygen species and enhanced ATP synthesis. Studies indicate that these mechanisms collectively contribute to improved cellular energy metabolism and reduced oxidative stress. Research investigations have consistently shown that SS-31 exhibits multiple protective effects across various cellular systems. In laboratory studies, the peptide demonstrates significant cardioprotective properties, suggesting potential applications in cardiovascular research models. Additionally, neuroprotective benefits have been observed in neurological research contexts, highlighting the compound's versatility in mitochondrial dysfunction studies. The peptide's classification as a mitochondrial compound reflects its targeted approach to cellular energy production. Unlike broader antioxidants, SS-31's specific interaction with cardiolipin allows for precise mitochondrial intervention, making it particularly valuable for researchers investigating mitochondrial disorders and age-related cellular dysfunction. Notably, SS-31 has achieved FDA approval under the name Forzinity for Barth syndrome treatment, marking it as the first FDA-approved mitochondria-targeted therapeutic. This regulatory milestone underscores the robust evidence base supporting the compound's biological activity and validates its potential for advancing mitochondrial research applications.